Show simple item record

dc.contributor.authorDe La Chapa, Jorge ( )
dc.contributor.authorSingha, Prajjal Kanti ( )
dc.contributor.authorSallaway, McKay ( )
dc.contributor.authorSelf, Kristen ( )
dc.contributor.authorNasreldin, Ranna ( )
dc.contributor.authorDasari, Ramesh ( )
dc.contributor.authorHart, Matthew ( )
dc.contributor.authorKornienko, Alexander ( )
dc.contributor.authorJust, Jeremy ( )
dc.contributor.authorSmith, Jason A. ( Orcid Icon 0000-0001-6313-3298 )
dc.contributor.authorBissember, Alex C. ( Orcid Icon 0000-0001-5515-2878 )
dc.contributor.authorGonzales, Cara B. ( )
dc.identifier.citationDe La Chapa, J., Singha, P. K., Sallaway, M., Self, K., Nasreldin, R. D., Dasari, R., Hart, M., Kornienko, A., Just, J., Smith, J. A., Bissember, A. C., & Gonzales, C. B. (2018). Novel polygodial analogs P3 and P27: Efficacious therapeutic agents disrupting mitochondrial function in oral squamous cell carcinoma. International Journal of Oncology, 53(6), pp. 2627–2636.en_US

Polygodial, a drimane sesquiterpenoid dialdehyde isolated as a pungent component of the water pepper Persicaria hydropiper, exhibits antifeedant, antimicrobial, anti-inflammatory and anticancer effects. Polygodial also activates transient receptor potential vanilloid subtype 1 (TRPV1) channels. Previously, we described the synthesis of a C12-Wittig derivative of polygodial, termed P3, with significant antiproliferative effects against multiple cancer types including oral squamous cell carcinoma (OSCC). In the present study, a more potent derivative, P27, with superior anti-proliferative effects in vitro and antitumor effects in Cal-27 derived xenografts is described. Polygodial, P3, and P27 all significantly decreased OSCC tumor growth, with P27 being equipotent with polygodial and P3 being the least efficacious. However, neither analog elicited the adverse effect observed with polygodial: Profound transient inflammation. Although P3 and P27 pharmacophores are based on polygodial, novel effects on OSCC cell cycle distribution were identified and shared anticancer effects that are independent of TRPV1 activity were observed.

Polygodial elicits an S-phase block, whereas P3 and P27 lead to G2/M phase arrest. Pretreatment of OSCC cells with the TRPV1 antagonist capsazepine does not affect the antiproliferative activity of P3 or P27, indicating that TRPV1 interactions do not regulate OSCC cell proliferation. Indeed, calcium imaging studies identified that the analogs neither activate nor antagonize TRPV1. Behavioral studies using a rat model for orofacial pain confirmed that these analogs fail to induce nocifensive responses, indicating that they are non-noxious in vivo. All compounds induced a significant concentration-dependent decrease in the mitochondrial transmembrane potential and corresponding apoptosis. Considering that P27 is equipotent to polygodial with no TRPV1-associated adverse effects, P27 may serve as an efficacious novel therapy for OSCC.

dc.format.extent10 pages
dc.format.medium1 file (.pdf)
dc.publisherSpandidos Publicationsen_US
dc.sourceInternational Journal of Oncology, 2018, Vol. 53, No. 6, pp. 2627–2636
dc.subjectOral squamous cell carcinoma
dc.subjectMitochondrial dysfunction
dc.titleNovel Polygodial Analogs P3 and P27: Efficacious Therapeutic Agents Disrupting Mitochondrial Function in Oral Squamous Cell Carcinomaen_US
txstate.departmentChemistry and Biochemistry



This item appears in the following Collection(s)

Show simple item record